High-efficiency lysis of cervical cancer by allogeneic NK cells derived from umbilical cord progenitors is independent of HLA status

Cancer Immunology, Immunotherapy

Volumn 66, Issue 1, 2017, Pages 51-61

  Veluchamy, John P ^a,b   Heeren, A Marijne ^a   Spanholtz, Jan ^b   van Eendenburg, Jaap D H ^c   Heideman, Daniëlle A M ^a   Kenter, Gemma G ^a   Verheul, Henk M ^a   van der Vliet, Hans J ^a   Jordanova, Ekaterina S ^a   de Gruijl, Tanja D ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Glycostem Therapeutics   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adoptive NK immunotherapy; Cervical cancer; CET; NK ligands and receptors; Peripheral blood NK cells; Umbilical cord blood stem cell derived NK cells

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; HLA E ANTIGEN; HLA G ANTIGEN; LIGAND; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MONOCLONAL ANTIBODY; NATURAL KILLER CELL RECEPTOR NKG2D; RAS PROTEIN; HLA ANTIGEN;

ARTICLE; BLOOD; CANCER CHEMOTHERAPY; CERVICAL CANCER CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; DEGRANULATION; HLA SYSTEM; HUMAN; HUMAN CELL; IN VITRO STUDY; MONOTHERAPY; NATURAL KILLER CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL; UMBILICAL CORD; UTERINE CERVIX CANCER; ALLOTRANSPLANTATION; CYTOLOGY; FEMALE; FETUS BLOOD; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; IMMUNOTHERAPY; PROCEDURES; TUMOR CELL LINE; UTERINE CERVICAL NEOPLASMS;

CELL LINE, TUMOR; FEMALE; FETAL BLOOD; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA ANTIGENS; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; PHENOTYPE; TRANSPLANTATION, HOMOLOGOUS; UTERINE CERVICAL NEOPLASMS;

EID: 84992376463     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-016-1919-1     Document Type: Article

References (50)

1. Trottier H, Franco EL (2006) The epidemiology of genital human papillomavirus infection. Vaccine 24(Suppl 1):S1–15
2. Woodman CB, Collins SI, Young LS (2007) The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 7:11–22
3. Steenbergen RD, Snijders PJ, Heideman DA, Meijer CJ (2014) Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions. Nat Rev Cancer 14:395–405
4. Zagouri F, Sergentanis TN, Chrysikos D, Filipits M, Bartsch R (2012) Molecularly targeted therapies in cervical cancer: a systematic review. Gynecol Oncol 126:291–303
5. Diaz-Padilla I, Monk BJ, Mackay HJ, Oaknin A (2013) Treatment of metastatic cervical cancer: future directions involving targeted agents. Crit Rev Oncol Hematol 85:303–314
6. Li Q, Tang Y, Cheng X, Ji J, Zhang J, Zhou X (2014) EGFR protein expression and gene amplification in squamous intraepithelial lesions and squamous cell carcinomas of the cervix. Int J Clin Exp Pathol 7:733–741
7. Kersemaekers AM, Fleuren GJ, Kenter GG, Van den Broek LJ, Uljee SM, Hermans J et al (1999) Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin Cancer Res 5:577–586
8. Schrevel M, Gorter A, Kolkman-Uljee SM, Trimbos JB, Fleuren GJ, Jordanova ES (2011) Molecular mechanisms of epidermal growth factor receptor overexpression in patients with cervical cancer. Mod Pathol 24:720–728
9. Hertlein L, Lenhard M, Kirschenhofer A, Kahlert S, Mayr D, Burges A et al (2011) Cetuximab monotherapy in advanced cervical cancer: a retrospective study with five patients. Arch Gynecol Obstet 283:109–113
10. Farley J, Sill MW, Birrer M, Walker J, Schilder RJ, Thigpen JT et al (2011) Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study. Gynecol Oncol 121:303–308
11. Menderes G, Black J, Schwab CL, Santin AD (2016) Immunotherapy and targeted therapy for cervical cancer: an update. Expert Rev Anticancer Ther 16:83–98
12. Connor ME, Stern PL (1990) Loss of MHC class-I expression in cervical carcinomas. Int J Cancer 46:1029–1034
13. Jordanova ES, Gorter A, Ayachi O, Prins F, Durrant LG, Kenter GG et al (2008) Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients? Clin Cancer Res 14:2028–2035
14. Akira S, Uematsu S, Takeuchi O (2006) Pathogen recognition and innate immunity. Cell 124:783–801
15. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S (2008) Functions of natural killer cells. Nat Immunol 9:503–510
16. Vitale M, Cantoni C, Pietra G, Mingari MC, Moretta L (2014) Effect of tumor cells and tumor microenvironment on NK-cell function. Eur J Immunol 44:1582–1592
17. Kobayashi A, Greenblatt RM, Anastos K, Minkoff H, Massad LS, Young M et al (2004) Functional attributes of mucosal immunity in cervical intraepithelial neoplasia and effects of HIV infection. Cancer Res 64:6766–6774
18. Textor S, Durst M, Jansen L, Accardi R, Tommasino M, Trunk MJ et al (2008) Activating NK cell receptor ligands are differentially expressed during progression to cervical cancer. Int J Cancer 123:2343–2353
19. Gooden M, Lampen M, Jordanova ES, Leffers N, Trimbos JB, van der Burg SH et al (2011) HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8+ T lymphocytes. Proc Natl Acad Sci USA 108:10656–10661
20. Renoux VM, Bisig B, Langers I, Dortu E, Clemenceau B, Thiry M et al (2011) Human papillomavirus entry into NK cells requires CD16 expression and triggers cytotoxic activity and cytokine secretion. Eur J Immunol 41:3240–3252
21. Jimenez-Perez MI, Jave-Suarez LF, Ortiz-Lazareno PC, Bravo-Cuellar A, Gonzalez-Ramella O, Aguilar-Lemarroy A et al (2012) Cervical cancer cell lines expressing NKG2D-ligands are able to down-modulate the NKG2D receptor on NKL cells with functional implications. BMC Immunol 13:7
22. Arreygue-Garcia NA, Daneri-Navarro A, Del Toro-Arreola A, Cid-Arregui A, Gonzalez-Ramella O, Jave-Suarez LF et al (2008) Augmented serum level of major histocompatibility complex class I-related chain A (MICA) protein and reduced NKG2D expression on NK and T cells in patients with cervical cancer and precursor lesions. BMC Cancer 8:16
23. Garcia-Iglesias T, Del Toro-Arreola A, Albarran-Somoza B, del Toro-Arreola S, Sanchez-Hernandez PE, Ramirez-Duenas MG et al (2009) Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions. BMC Cancer 9:186
24. Spaans VM, Peters AA, Fleuren GJ, Jordanova ES (2012) HLA-E expression in cervical adenocarcinomas: association with improved long-term survival. J Transl Med 10:184
25. Gimenes F, Teixeira JJ, de Abreu AL, Souza RP, Pereira MW, da Silva VR et al (1846) Human leukocyte antigen (HLA)-G and cervical cancer immunoediting: a candidate molecule for therapeutic intervention and prognostic biomarker? Biochim Biophys Acta 576–589:2014
26. Cho H, Chung JY, Kim S, Braunschweig T, Kang TH, Kim J et al (2014) MICA/B and ULBP1 NKG2D ligands are independent predictors of good prognosis in cervical cancer. BMC Cancer 14:957
27. Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA et al (2011) A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 13:98–107
28. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK et al (2005) Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105:3051–3057
29. Geller MA, Miller JS (2011) Use of allogeneic NK cells for cancer immunotherapy. Immunotherapy 3:1445–1459
30. Spanholtz J, Preijers F, Tordoir M, Trilsbeek C, Paardekooper J, de Witte T et al (2011) Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PLoS ONE 6:e20740
31. Seidel UJ, Schlegel P, Lang P (2013) Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies. Front Immunol 4:76
32. Lehmann D, Spanholtz J, Osl M, Tordoir M, Lipnik K, Bilban M et al (2012) Ex vivo generated natural killer cells acquire typical natural killer receptors and display a cytotoxic gene expression profile similar to peripheral blood natural killer cells. Stem Cells Dev 21:2926–2938
33. Koopman LA, Szuhai K, van Eendenburg JD, Bezrookove V, Kenter GG, Schuuring E et al (1999) Recurrent integration of human papillomaviruses 16, 45, and 67 near translocation breakpoints in new cervical cancer cell lines. Cancer Res 59:5615–5624
34. Heideman DA, Thunnissen FB, Doeleman M, Kramer D, Verheul HM, Smit EF et al (2009) A panel of high resolution melting (HRM) technology-based assays with direct sequencing possibility for effective mutation screening of EGFR and K-ras genes. Cell Oncol 31:329–333
35. Heideman DA, Lurkin I, Doeleman M, Smit EF, Verheul HM, Meijer GA et al (2012) KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA. J Mol Diagn 14:247–255
36. Spanholtz J, Tordoir M, Eissens D, Preijers F, van der Meer A, Joosten I et al (2010) High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy. PLoS ONE 5:e9221
37. Campbell KS, Hasegawa J (2013) Natural killer cell biology: an update and future directions. J Allergy Clin Immunol 132:536–544
38. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME (2008) Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8:299–308
39. Wang M, Yin B, Wang HY, Wang RF (2014) Current advances in T-cell-based cancer immunotherapy. Immunotherapy 6:1265–1278
40. Rezvani K, Rouce RH (2015) The application of natural killer cell immunotherapy for the treatment of cancer. Front Immunol 6:578
41. Stevanovic S, Draper LM, Langhan MM, Campbell TE, Kwong ML, Wunderlich JR et al (2015) Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol 33:1543–1550
42. Goncalves MA, Le DM, Simoes RT, Rabreau M, Soares EG, Donadi EA, Carosella ED (2008) Classical and non-classical HLA molecules and p16(INK4a) expression in precursors lesions and invasive cervical cancer. Eur J Obstet Gynecol Reprod Biol 141:70–74
43. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G et al (2010) Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11:753–762
44. Bellone S, Frera G, Landolfi G, Romani C, Bandiera E, Tognon G et al (2007) Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for cetuximab-mediated therapy in recurrent/metastatic disease. Gynecol Oncol 106:513–520
45. Meira DD, de Almeida VH, Mororo JS, Nobrega I, Bardella L, Silva RL et al (2009) Combination of cetuximab with chemoradiation, trastuzumab or MAPK inhibitors: mechanisms of sensitisation of cervical cancer cells. Br J Cancer 101:782–791
46. Warren HS, Smyth MJ (1999) NK cells and apoptosis. Immunol Cell Biol 77:64–75
47. Boerman GH, van Ostaijen-ten Dam MM, Kraal KC, Santos SJ, Ball LM, Lankester AC et al (2015) Role of NKG2D, DNAM-1 and natural cytotoxicity receptors in cytotoxicity toward rhabdomyosarcoma cell lines mediated by resting and IL-15-activated human natural killer cells. Cancer Immunol Immunother 64:573–583
48. Vieillard V, Baychelier F, Debre P (2014) NKp44L: a new tool for fighting cancer. Oncoimmunology 3:e27988
49. Cheng M, Chen Y, Xiao W, Sun R, Tian Z (2013) NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol 10:230–252
50. Cany J, van der Waart AB, Tordoir M, Franssen GM, Hangalapura BN, de Vries J et al (2013) Natural killer cells generated from cord blood hematopoietic progenitor cells efficiently target bone marrow-residing human leukemia cells in NOD/SCID/IL2Rg(null) mice. PLoS ONE 8:e64384